Komo

Intellia Therapeutics

Who are Intellia Therapeutics's decision-makers?

Intellia Therapeutics's official leadership and governance pages are the safest source for named executives.

Primary buyers
Finance, procurement, IT, security, operations, legal, and business leadership
Company status
Public company; Nasdaq: NTLA
HQ
Cambridge, United States
Category
Genome editing therapeutics company
Decision style
Public-company buying committee
Best source
Official leadership or IR page
  • Intellia Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
  • Intellia Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
  • Intellia Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.

Who leads Intellia Therapeutics?

Intellia Therapeutics's named leaders should be verified directly on the company's official leadership, governance, or investor-relations page.

Who owns buying decisions at Intellia Therapeutics?

The buying committee depends on the offer and usually spans finance, procurement, legal, IT/security, and the business owner.

How should sellers map the account?

Start with headquarters and public leadership, then map functional owners by product area, job posts, filings, partner announcements, and investor materials.

As of June 2026.Sources:Intellia Therapeutics official websiteIntellia Therapeutics investor relations or company newsBuiltWith public technology profile

Intellia Therapeutics — frequently asked questions

Agent CTA Background

Revenue work. On autopilot.

Start Free TrialBuilt for revenue teams who care about quality.